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Purpose: A clinical trial of intestinal transplantation (ltx) 
under tacrolimus and prednisone immunosuppression was 
initiated in June 1990 in children with irreversible intestinal 
failure and who were dependent on total parenteral nutrition 
(TPN). 
Methods: Fifty·five patients (28 girls. 27 boys) with a median 
age of 3.2 years (range. 0.5 to 18 years) received 58 intestinal 
transplants that included isolated small bowel (SS) (n = 17). 
liver SS (LSS) (n = 33). and multivisceral (MV) (n = 8) allo· 
grafts. Nine patients also received bone marrow infusion. 
and there were 20 colonic allografts. Azathioprine. cyclophos-
phamide. or mycophenolate mofetil were used in different 
phases of the series. Indications for It x included: gastroschi-
sis (n = 14). volvulus (n = 13). necrotizing enterocolitis (n = 61. 
intestinal atresia (n = 8). chronic intestinal pseudoobstruc-
tion (n = 5). Hirschsprung's disease (n = 4). microvillus inclu-
sion disease (n = 31. multiple polyposis (n = 11. and trauma 
(n = 1). 
Results: Currently. 30 patients are alive (patient survival. 55%; 
graft survival. 52%). Twenty-nine children with functioning 
grafts are living at home and off TPN. with a mean follow-up 
of 962 (range. 75 to 2.424) days. Immunologic complications 
have included liver allograft rejection (n = 181. intestinal 
allograft rejection (n = 52), posttransplant Iymphoprolifera-
T HE EVOLUTION of experimental and clinical intes-
tinal transplantation has been through several devel-
opmental phases over the last three decades. The pioneer-
ing experimental models in dogs by Lillehei et all in 
1959, and then subsequently the transplantation of the 
small intestine as part of a multi visceral composite graft 
by Starztl I year later established the technical basis for 
the transplantation of the intestine alone or with other 
organs. Many auempts at clinical intestinal transplanta-
tion were performed after 1964. initially under azathio-
prine/steroid immunosuppression, and then subsequently 
using cyclosporine/steroids.3 Unlike other organs. clini-
cal success was almost unknown because of a high 
incidence of graft loss caused by technical complications 
and rejection. Also. the established unidirectional para-
digm of transplantation and immunology found with 
bone marrow transplantation' and direct experimenta-
tionS predicted that graft-versus-host disease (GVHD) 
would be precipitated through the immunocytes in the 
lymphoid-rich. major histocompatibility complex dispar-
ate intestinal allograft. 
These precepts were applied in a modified form..of this 
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tive disease (n = 16). cytomegalovirus (n = 16) and graft-
versus-host disease (n = 4). A combination of associated 
complications included intestinal perforation (n = 4). biliary 
leak (n = 3). bile duct stenosis (n = 11. intestinal leak (n = 6). 
dehiscence with evisceration (n = 4). hepatic artery thrombo-
sis (n = 3). bleeding (n = 9). portal vein stenosis (n = 1). 
intraabdominal abscess (n = 11). and chylous ascites (n = 4). 
Graft loss occurred as a result of rejection (n = 8). infection 
(n = 12). technical complications (n = 8). and complications 
of TPN after graft removal (n = 3). There were four retrans-
plants (SS. n = 1; LSB n = 3). 
Conclusions: Intestinal transplantation is a valid therapeutic 
option for patients with intestinal failure suffering complica-
tions of TPN. The complex clinical and immunologic course 
of these patients is reflected in a higher complication rate as 
well as patient and graft loss than seen after heart. liver. and 
kidney transplantation. although better than after lung trans-
plantation. 
J Pediatr Surg 33:243-254. Copyright c> 1998 by W.B. Saun-
ders Company. 
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operation in 1987 with a 3-year-old reCIpient of a 
multivisceral abdominal graft that contained the stomach. 
duodenum. pancreas, small bowel. colon. and the liver.6 
This was the first long-term survivor (6 months) of a 
functioning human intestinal graft. The dogmatic deple-
tion of graft T lymphocytes by infusing the donor with 
OKT3 treatment before procurement and by ex vivo 
irradiation after their removal was believed to have 
precipitated the wide spread B cell lymphoma that caused 
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the death of this child. Subsequent limited success was 
achieved with cadaveric intestinal grafts transplanted 
alone, as liver/intestinal composite grafts. or as multi vis-
ceral allografts.7• lo A living-related donor intestinal seg-
ment was transplanted by Deitz in February 1988, which 
supported nutrition for 61 months. I I 
The clinical application of intestinal transplantation 
was abruptly changed after 1989 by the emergence of 
FK506 (now tacrolimus). This superior immunosuppres-
sant allowed rat and human intestinal grafts (alone or as 
part of a multivisceral complex) to be transplanted with 
routine success. 12.13 Also, the appreciation of the duality 
of the immune reaction after organ transplantation (host-
versus-graft and graft-versus-host) has been postulated as 
the two-way paradigm of transplantation immunology.14 
Here, two cell populations (of recipient and donor origin) 
reciprocally modulate immune responsiveness, including 
the induction of mutual nonreactivity with consequent 
organ allograft acceptance. 15 The expectation that intesti-
nal transplantation would be feasible under these condi-
tions has been realized and permitted the rapid growth of 
this field. We report here the first 55 pediatric recipients 
of intestinal allografts treated with this drug. 
MATERIALS AND METHODS 
Case Material 
Between June. 1990 and January 1997. 55 children received 58 
intestinal transplants. which included isolated small bowel (SB. n = 17). 
liver/small bowel (LSB. n = 33). and multivisceral (MV. n = 8) 
Jllografts. Two patients also received kidney allografts. There were 28 
girls and 27 boys with age ranging between 0.5 to 18 years (median. 3.2 
years). The average patient weight al the time of transplantation WJS 18 
(range. 5.2 10 65.6) kg. 
The diseases leJtiing 10 IOtestinal failure included anatomic ("surgi· 
cal") causes with a small length of bowel after resections. and 
functional ("nonsurgical") CJuses such as motility disorders and 
secretory/absorptive deficiencies (Table I). All patients were dependant 
on t01a1 pJrenteral nutrition (TPN) for a median time of 24 months 
(range. 6 to 180 months). and had experienced multiple episodes of 
TPN·related complications such as line sepsis. major vessel thrombosis. 
or hepalic dysfunction. Two patients were previous recipients of liver 
allografts. Evaluation of candidates were as previously described. 16 A 
total of 182 patients have been followed up. which included the 55 
transplant recipients and 127 patients who did not undergo transplanta-
tion. 
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These 55 children had undergone an average of tWO (range. zero to 
seven) previous laparotomies. Only four retained the large bowel 
including the ileocecal valve. The average length of the remaining 
proximal small bowel was 9.7 (range, 0 to 50) cm. and 16 patients had 
no remaining small bowel. The median bilirubin level at the time of 
transplant was 8.3 (range, 0.4 to 44.1) mg/dL. All of the patients were 
followed up until March 30,1997. The mean follow-up was 962 (range. 
75 to 2424) days. 
Donors 
The intestinal grafts were obtained from ABO blood type-identical 
cadaveric donors. Acceptable weight ranges included 50'k less than to 
20% greater than the recipient weight. This range was permissible 
because of the larger abdominal cavity in recipients suffering end· stage 
liver disease and the potential of shonening the bowel length in 
recipients of an isolated SB graft. The median donor age was 2 (range. 
0.3 to 34) years. and the average weight was I g (range. 5.2 to 65.6) kg. 
Donor management and operative technique were as previously de· 
scribed. t7tS Conceptually. the organs were isolated preserving their 
vascular and parenchymal anatomy. and perfused with chilled Univer-
sity of Wisconsin solution. Cold ischemia time from aonic clamping 
until graft reperfusion averaged 7.83 (range. 2.8to 14.8) hours. None of 
the allografts had evidence of significant organ preservation damage. 
Lymphocytotoxic cross match was strongly positive in seven patients. 
Matching of human leukocyte antigen (HLA) was random. Graft 
pretreatment to deplete the lymphoid tissue in the intestinal allograft 
was not performed. Luminal flushing was performed only when a 
segment of allograft colon was used. Systemic antibiotics. and intestinal 
decontamination was used in all donors as previously described. 19 
Transplallt Operation 
The liver was included as pan of the allograft when there was 
TPN-induced end-stage liver disease. Inclusion of other portions of the 
gastrointestinal tract was dictated by the presence of extensive func-
tional disease in the remaining gastrointestinal tract. The mean opera-
tive time was 13.2 (range, 5.6 to 24.6) hours. This was significantly 
shoner for the SB operation. which had a median time of 9.6 (range. 7.8 
to 24.6) hours versus the LSB median procedure time of 13.5 (range. 5.6 
to 22.5) hours, or the MY median time of 13.1 (range. 12.1 to 16.2) 
hours (P < .05). 
The patients given the isolated SB grafts had principally major vessel 
access complications (n = 6) or frequent episodes of infection (n = 8) 
in the face of minor liver function abnormalities (n = 6). In this group, 
results of liver biopsy performed at the time of transplant showed 
significant fibrosis in 13 (80%) patients. The 58 graft was based on a 
vascular pedicle of superior mesenteric anery and superior mesenteric 
vein. The venous return was directed into the recipients ponal vein 
(n = 8). superior mesenteric vein (n = 4). splenic vein (n = I), and the 
inferior vena cava (n = 4). Six patients had an interposition venous 
graft to the ponal vein (Fig I). 
For the LSB and M V procedures. the graft was anastomosed 
"piggyback" to the skeletonized recipient vena cava. and anerialized 
from the infrarenal aorta via an aortic conduit homogrolft (Fig 2A and 
B).ln the LSB recipients. a permanent native portocaval shunt (n = 22) 
or a donor ponal vein to native ponal vein anastomosis (n = 10) was 
performed (Fig 2C). Two patients with a normal native liver received a 
modified MY procedure. which excluded the allograft liver as pan of 
the composite of organs. In these cases. the portal venous return was 
directed into the recipient portal vein (Fig 20). Reconstruction of the 
gastrointestinal and biliary ducts was with conventional techniques. In 
the first three cases. both ends of the intestlOal graft were exteriorized by 
the "chimney" method. Subsequemly. a tube jejunostomy replaced the 
chimney proximally. 
When the recipient became independent of TPN. the enterostomies 
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Fig 1. (AI Isolated intestinal graft. (B) Arterialization and potential venous drainage options in the isolated intestinal graft. pV, portal vein; sv, 
splenic vein; SMV, superior mesenteric vein; IYC, inferior vena cava. 
were taken down with an elltraperilOneal technique. at a median time of 
113 (range. 21 to 516) days. Because of high postoperative stomal 
outputs and the need for continuous intravenous fluid therapy. 20 grafts 
contained a segment of colon that was distributed among all three 
recipient cohorts: SB (n = 4), LSB (n = 10), and MV (n = 6). Two 
patients (one with Hirschsprung's disease and another with familial 
polyposis) had endorectal pull-through procedures performed with 
allograft colon.2O [n seven recipients. the donor celiac ganglion was 
preserved in an attempt to facilitate reinnervation and consequently 
improve the motility of the allograft bowel. 
Bone Marrow Transplantation 
Augmentation of leukocyte chimerism was performed in nine 
patients. (eight primary and one retransplantation) by giving unaltered 
adjuvant donor bone marrow isolated from the thoracolumbar vertebrae 
of the donor. as previously described.ll ·n 
Immunosuppression 
Postoperative immunosuppression was ba.<;Cd on tacrolimus (FK506. 
Prograt) and steroids. Briefly. intravenous tacrolimus was started 
intraoperatively at a dose of 0.15 mglkg/d and converted to an oral dose 
when patients could tolerate oral intake. Plasma l2-hour trough levels 
of tacrolimus were measured daily initially by enzyme-linked immuno-
assay technique (ELISA) (target therapeutic level between I and 2 
nglmL). then subsequently by whole blood levels. which were per-
formed using micropanicle enzyme immunoassay (MEIA) technology 
(trough target levels of 15 to 30 nglmL). Hydrocortisone (25 mglkg) or 
methylprednisolone (\0 mglkg) was given immediately after graft 
reperfusion. This was followed by an intravenous methylprednisolone 
taper over 5 days from a starting dose of 5 mglkgld. Azathioprine (I to 2 
mglkg/d) was added in selected patients to avert tacrolimus-induced 
renal tOllicity or enhance baseline immunosuppression in cases of 
recurrent rejection. The last 16 recipients received induction therapy 
using cyclophosphamide intravenously (2 mglkgld). and then were 
subsequently switched to either mycophenolate mophetil (15-30 mg/kg 
twice a day) or azathioprine. Prostaglandin EI was started intraopera-
tively at O.03l1glkglmin and gradually increased to 0.09 lIg/kglmin until 
intravenous tacrolimus was discontinued. This was given both for its 
beneficial effects on renal perfusion as well as for its prevention of 
microvascular thrombosis. the damage-mediating event in acute cellular 
rejection and procurement injury. H 
Rejection was treated initially with intravenous bolus methylpredniso-
lone (10 mglkg) and optimization of tacrolimus levels (either intrave-
nously or orally). Methylprednisolone taper therapy (similar to induc-
tion tapering doses) was used in cases of more severe rejection or when 
bolus therapy was inadequate. The use of OKT3 was the nellt line of 
therapy when steroid resistance occurred. 
For the initial cohort of patients. weekly allograft mucosal biopsies 
were performed endoscopicaly. alternating with occasional cup forceps 
biopsies near the ileostomy. Subsequently. surveillance was performed 
only endoscopically with mucosal biopsies. which were performed 
twice weekly for the transplant admission. and then whenever clinically 
indicated thereafter. The histological diagnoses of rejection has been 
described elsewhere. !S.26 
Surveillance of Graft- Versus-Host Disease 
All suspicious skin lesions were biopsied and studied by routine 
histology testing. Detection of donor cells by immunohistologic stain-
ing for donor-specific HLA antigens and in situ hybridization technique 
using the Y chromosome-specific probe have been described else-
where. ls 
Prevention of Infection 
All recipients received intestinal decontamination with polymyxin. 
tobramycin. and amphotericin B via the nasogastric tube for 2 weeks 
postoperatively. Weekly quantitative stool cultures were performed to 
assess overgrowth of resistant bacteria in greater than 108. 




Fig 2. lAI Liver small bowel graft. (BI Complete multivisceral graft. (CI 
Systemic porta caval shunt, and recipient portal vein to donor portal vein 
anastomosis (insetl. (01 Modified multivisceral graft. 
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specific antimicrobial therapy was given for infections the patient may 
have had before transplant. The antiviral prophylactic strategy evolved 
during the study period. Twelve patients who underwent transplant 
between July 1990 and July 1992 received prophylaxis with oral 
acyclovir (gOO mg/m2) four times a day for 12 weeks after transplanta-
tion. Forty-three patients received intravenous gancyclovir (10 mg/ 
kg/d) divided in two doses for the first 2 weeks after transplantation. 
Twenty of the 43 subsequently received oral acyclovir for an additional 
10 weeks. Seven of these 43 were given concomitant cytomegalovirus 
(CMV)-specific hyperimmuneglobulin (Cytogam. 100 mg/kg/d. Medim-
mune. Gaithersburg. MO). Antifungal therapy was used prophylacti-
cally only if there was evidence of prior infection. or at reexploration for 
any complication. Long-term protozoal prophylaxis was with trim-
ethoprim-sulfamethoxazole. 
NutritionaL Management 
Standard TPN formulas were tapered gradually as oral or enteral 
feedings (via gastric or jejunal tube) were advanced. Tube feedings are 
initiated with an isotonic dipeptide formula containing medium-chain 
triglycerides and glutamine. This was later converted to a lactose-free 
and gluten-free diet that contained dietary fibers to promote normaliza-
tion of intestinal motility and function. Most patients did not voluntarily 
eat adequate amounts early after the operation: therefore. enteral 
supplementation was required as soon as the intestinal tract became 
functional. This resistance to resumption of oral feeding has been 
particularly impressive in children. 
StatisticaL Methods 
Patient survival was calculated from the date of transplantation until 
death. Isolated SB recipients submitted to allograft enterectomy were 
censored at the time of discharge. because these patients may succumb 
to TPN-associated causes not related to the transplant procedure or 
immunosuppression. The primary graft survival was calculated from the 
date of transplantation until graft removal. retransplantation. or death. 
Survival curves were generated using the Kaplan-Meier method and 
compared by log rank (Mantel-Cox) test. The Pearson "ltest or Fisher's 
Exact test were used to compare proportions. 
RESULTS 
Patient and Graft SurvivaL 
Thirty of 55 patients are still alive. All except six of the 
30 surviving patients have a potential follow-up of at 
least I year (range. 0.2 to 6.7 years). The actuarial patient 
and primary graft survival rates at I. 3. and 5 years are 
72%. 55%. and 55% for patient. and 66%. 48%. and 48% 
for graft. respectively (Fig 3). Of note. during this time. 
the I and 2 year survival of patients who have not 
undergone transplantation has been 30% and 22%. respec-
tively. 
IsoLated IllIestinal Grafts 
This type of graft provided better patient survival and 
succeeded in restoring alimentary function at the highest 
rate at all follow-up times (range. 0.2 to 5.8 years). 
Actuarial survival rates at I. 3. and 5 years was 92% 
consistently for patient. and 73%. 61 %. and 61 % for the 
primary graft. respectively. All surviving patients who 
retained their graft have been liberated from TPN. 
Recently. one recipient was hospitalized with acute 
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Fig 3. Overall patient and graft survival rates. Of note is the 
survival rate of similar patients who did not reeeive a transplant. 
pancreatitis and is on partial TPN. Five graft losses 
occurred at 27. 54. 119.332. and 774 days posttransplant. 
respectively. all as a result of untreatable rejection. two of 
them in the setting of posttransplant Iymphoproliferative 
disease (PTLD) (Fig 4). Of note. the three censored 
patients died of TPN-related causes at 94. 459. and 496 
days postgraft removal. 
Liver Small BoweL 
Thirty-two recipients received 33 LSB grafts. of which 
15 (47%) are alive 0.5 to 6.7 years after operation. The 
actuarial survival rates at I. 3. and 5 years was 65%. 44%. 
and 44% for patient. and 63%. 45%. and 45% for the 
primary graft. respectively. All survivors are at home 
with functioning grafts (Fig 4). 
Multivisceral 
There were seven primary and one retransplant MY 
graft recipients. of which three patients are alive and TPN 
free. The actuarial 1-. 3-. and 5-year survival rates were 
57%. 43%. and 43% for patient and primary graft 
survival. respectively (Fig 4). 
RetrallspLantatioll 
Four patients underwent retransplantation. three LSB 
recipients on the same day as primary graft removal. and 
one SB recipient at 340 days after graft enterectomy. 
These patients lost their primary graft to acute intestinal 
rejection (n = 2). chronic intestinal rejection (n = I). 
PTLD (n = I). and hepatic artery thrombosis (n = I). Of 
the three LSB recipients. one patient received an MY 
retransplant. one patient received a liver-only retrans-
plant after hepatic artery thrombosis. and another patient 
received another LSB retransplant after acute rejection 
and adenovirus hepatitis. The three LSB recipients died at 
19 days. 47 days. and 57 days after the retransplantation 
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Fig 4. (AI Patient survival rate by type of graft. *indicates 5B 
survival censored recipients whose follow-up was terminated after 
allograft enterectomy. (BI Graft survival by type of graft. 
and PTLD (n = I). One S8 recipient received an S8 
graft at retransplant 11 months after graft enterectomy. 
This patient, who is alive, was also given bone marrow 
from the second intestinal donor. 
Influence of the Allograft Colon and Donor Bone 
MarroII' Augmentation 
Although inclusion of allograft colon did not statisti-
cally affect survival, there was a trend toward an increase 
in patient and graft loss in recipients of this intestinal 
segment (Fig 5). The actuarial survival at 1,3, and 5 years 
was 56%, 39%, and 39% for primary graft survival and 
64%, 45%. and 45% for patient survival when the 
allograft colon was part of the intestinal allograft versus a 
survival of 71 %, 51 %, and 51 % for graft and 70%, 59%, 
and 59% for patient, respectively when the allograft 
colon was not included (Fig 4). Although the potential 
functional advantage in weaning time of TPN or intrave-
nous fluids when compared with patients who did not 
recei ve allograft colon was not seen, the allograft colon 
was successfully used as a reconstructive segment in two 
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patients who required a pull-through procedure because 
of disease involving the rectum. 
The bone marrow augmentation trial included a cohort 
of 22 patients, of which nine received donor bone 
marrow. There was no significant difference in actuarial 
patient or graft survival between the two groups at I and 2 
years. 
Nutritional Status 
Currently, 29 of 30 children (97%) have been weaned 
offTPN. The median time of weaning has been 41 (range, 
14 to 210) days. Enteral feeding (Pediatric Vivonex or 
Tolerex) was introduced at a median of 9 days posttrans-
plant (range, 3 to 37). Twenty-three (77%) of these 
children thrive on oral diet alone. Two children receive 
tube feedings only because of the refusal to eat, and are 
currently in feeding therapy. Four other children take oral 
feeds during the day and receive supplemental night time 
feeds until their oral intake is adequate to support growth. 
The hospitalized recipient of an S8 graft is transiently on 
TPN because of acute pancreatitis. Food allergies were 
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common, and include lactose (n = 5), and gluten (n = 3) 
agents. 
Vitamin A, B 12, red blood cell count (RBC) folate, 
zinc, and selenium were drawn immediately posttrans-
plant, then 3 and 6 months after TPN was discontinued, 
RBC folate and zinc levels were commonly found to be 
abnormal posttrans·plant. High stomal outputs contributed 
to abnormal serum zinc status, and these children were 
given supplements accordingly. Abnormal serum RBC 
folate levels are currently being investigated, but could be 
related to bacterial overgrowth. One patient suffered 
severe copper deficiency and is presently on supplemen-
tation, 
Anthropometrics were not taken in children less than I 
year of age, because the results are insignificant. The 
majority of children were in the 50th to 90th percentile 
for weight and height pretransplant secondary to growth 
retardation and ascites. Posttransplant weight decreased 
as ascites and body fat were lost after TPN was discontin-
ued. Linear growth continued post-TPN as adequate 
calories were provided via oral and/or enteral routes. The 
greatest linear growth was seen in children I to 5 years of 
age. Midarm muscle circumference and triceps skin fold 
values posttransplant reflected maintenance of muscle 
and fat stores, 
The recovery time was shorter in recipients of SB 
grafts (median intensive care unit [ICUI stay of 5, range, 
2 to 34 days; hospital stay of 9, range, 3 to 27 weeks) 
when compared with recipients of LSB (lCU stay of 7, 
range, 3 to 300 days; hospital stay of 9, range, 5 to 45 
weeks), and MV recipients (ICU stay of 17, range, 3 to 30 
days; hospital stay of 12.4, range, 8 to 21 weeks; 
P = .001 for ICU stay only). However, there was no 
statistical significance in discharge time. 
Influence of Age and UNOS Status 
Although our initial experience suggested a significant 
adverse effect in UNOS status I recipients (lCU bound, 
less than 7 days survival), with better patient manage-
ment this has increased to 62%, which is comparable to 
UNOS status II (hospitalized, 43%) and UNOS status III 
(at home, 62% P = NS). The best survival was in 
recipients age greater than 10 years (89%). Survival in 
recipients 0 to 2 years of age was 43%, 2 to 5 years was 
56%, and 5 to 10 years was 44%. 
Complications 
Rejection. The overall incidence of rejection of the 
intestinal allograft was 90%, with a mean of 2.9 :t 2.7 
episodes per graft. Rejection of the liver allograft when it 
was part of the composite transplant occurred in 43% of 
cases with a mean of 1.2 :t 1,8 episodes. The first episode 
of intestinal rejection appeared a median of 14 days 
(range. 3 to 42 days). and the first episode of liver 
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allograft rejection appeared a median of 57 days (range. 6 
to 275 days). 
The incidence of intestinal allograft rejection in the 
first 30 days after transplant according to graft type was 
SB, 88%; LSB, 66%; and MV, 75% (P = .02). This was 
not affected statistically by bone marrow augmentation 
(P = .2) or the inclusion of allograft colon (P = .2). The 
use of cyclophosphamide was associated with a higher 
incidence of rejection when compared with patients who 
did not receive this drug ( 100% v 65%, P = .000 I). Also, 
the use of OKT3 for the treatment of severe rejection was 
more common in recipient of SB grafts (76%) versus 
recipients of LSB (21%, P = .007) or MV (50%) grafts 
(P = NS). 
Infection. Infectious pathogens included bacteria, 
fungi, and viruses. Of the bacterial pathogens staphylo-
cocci and enterococci were common, whereas gram-
negative rods usually accompanied polymicrobial infec-
tions in the face of a surgical complication. Fungal 
infections in children have included treatable yeast 
organism in the abdominal cavity. and untreatable sys-
temic aspergillosis (two patients). 
The association of bacteremia or fungemia with pathol-
ogy of the intestinal allograft has been previously re-
portedY Enteric organisms as well coagulase-negative 
staphylococcus were recovered during episodes of docu-
mented rejection as well as PTLD. 
Viral infections have been principally cytomegalovirus 
(CMV) and Epstein-Barr virus (EBV). However. signifi-
cant morbidity has been seen with adenovirus, respiratory 
syncytial virus. influenza. and rota virus. 
EBV-associated PTLD has occurred in 16 children 
(29%). These cases were distributed relati ve to graft type 
as follows: SB (n = 4, 29%); LSB (n = 9, 27%), MV 
(n = 3,50%). There were a total of 18 episodes of PTLD 
among these 16 recipients. Two patients presented more 
than one episode of PTLD after successful resolution of 
prior episodes. Persistent intractable disease was seen in 
seven patients, with death occurring in all of them. Most 
patients presented with nonspecific signs and symptoms. 
however, three were totally asymptomatic and discovered 
to have PTLD during a routine endoscopy. The intestinal 
allograft was involved in 14 patients. Three patients had 
involvement of the thoracic cavity. Fulminant disease 
was seen in one patient, and five patients had PTLD 
diagnosed at autopsy. Significant risk factors were found 
to be the number of rejection episodes, the use of OKT3. 
splenectomy, and age,28 Therapy included reduction and 
withdrawal of immunosuppression. antivirals (gancyclo-
vir, hyperimmuneglobulin cytogam), cytokines (inter-
feron alfa), and chemotherapy. Resolution of this disease 
was accomplished in four patients. Rebound rejection 
was a significant contributor to morbidity and mortality 
with this disease.28 
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CM V disease developed in 16 patients (29%), and they 
were stratified by donor/recipient (DIR) serologic status 
into D+/R- (7 of 12 58%), D+IR+ (3 of 9 33%), 
D-IR+ (6 of 14 43%), and D-IR- (0 of 20 0%). The 
intestinal aJlograft was affected in 91 % of the patients in 
whom disease developed; in three patients CMV also 
invaded native stomach, duodenum, and colon. Pneumo-
nitis occurred in four patients. The mismatched patients 
(D+IR -) showed a higher recurrence of disease (57%) 
when compared with D+IR+ (33%), or D-/R+ (33%) 
patients. Persistent disease was seen in three D+IR-
patients, but not in other cases. Mismatched patients also 
experienced involvement of the native intestine (43%) 
and CMV hepatitis (29%), which did not occur in the 
other groups. Disease in the mismatched patients was 
more aggressive with involvement of central nervous 
system (n = I) and retina (n = 2), which required intra-
ocular antiviral therapy. In two patients with persistent 
CMV disease, antiviral resistance developed into ganci-
c10vir (n = 2) and foscamet (n = I), which was associ-
ated with chronic active disease. CMV disease was 
significantly more likely to occur among patients in 
whom the donor and/or recipient were positive (P < .05). 
However. no differences were found in actuarial patient 
or graft survival among the different serological sub-
groups. Successful clinical management was accom-
plished in 88% of episodes of CMV disease using 
ganciclovir alone or in combination with CMV specific 
hyperimmunoglobulin. Immunosuppression was main-
tained at a therapeutic base line and reduced only in the 
face of deteriorating clinical disease.29 
Graft-versus-host disease. Minor skin changes con-
sistent with GVHD were observed in 4 of 55 patients 
(7%), and diagnosed by histopathologic criteria, which 
included keratinocyte necrosis, epithelial apoptosis of 
native gastrointestinal tract, or epithelial cell necrosis of 
oral mucosa. Donor ceJl infiltration into the lesions were 
examined and confirmed by immunohistochemical method 
on two occasions. Of interest, two episodes appeared 5 
and 6 days, respectively, after removal of the intestinal 
allograft, and was responsible for significant morbidity in 
one patient. GVHD in all but one patient resolved 
spontaneously. One death occurred in a young girl with 
hereditary IgG and IgM deficiency. Infectious complica-
tions led to her death after septicemia in the presence of 
GVHD, which was diagnosed 4 days after stopping 
immunosuppression. 3O Of these four patients. none re-
ceived donor bone marrow augmentation. 
Surgical complications. Complications occurred in 
26 recipients (47%), and are noted in Table 2. The most 
common were intraabdominal infection. which was usu-
ally consequent to other technical events. such as hepatic 
thrombosis. biliary or intestinal anastomotic leaks. and 
intestinal perforations. These complications were signifi-
cant contributors to morbidity and mortality. Graft-
Table 2. Surgical Complications 
Intestinal perforation 
Intestinal anastomotic leak 
Biliary leak 
Biliary stricture 
Hepatic artery thrombosis 














associated vascular complications included hepatic artery 
thrombosis (which was responsible for death in three 
recipients) and portal vein stenosis in an SB recipient that 
was treated successfully with angioplasty. 
Cause of graft loss. Twenty-eight (48%) of the 58 
grafts were lost by either recipient death or as a result of 
intestinal graft enterectomy. The principal diagnosis was 
rejection in eight cases. Opportunistic infections as a 
complication attributable to antirejection therapy was the 
major diagnosis in the loss of 12 grafts. of which. eight 
were caused by PTLD. Technical failures. which in-
cluded vascular. intestinal. and biliary. were responsible 
for the loss of eight grafts. Rejection in association with 
PTLD was responsible for graft loss in five cases. In 
general, although the cause of graft loss could be traced to 
the above events, their unfolding was invariably multifac-
torial and complex. 
DISCUSSION 
This experience demonstrates the feasibility and life-
saving potential of intestinal transplantation in children. 
The most encouraging results have been with the intes-
tine alone (SB) graft. which supports previous reports by 
us and others.8.31-33 This reflects not only the overall 
health status of the recipient at the time of transplantation 
(they are not suffering from failure of any other organ 
system), but also the shorter operative time, intensive 
care unit stay. overall hospital stay. and ease with which 
patients make the transition to oral/enteral diets. This 
advantage was notable inspite of the increased incidence 
of rejection. Although the survival rate with the LSB and 
MV operations is significantly inferior to the SB proce-
dure. these procedures are uniquely suited to the type of 
patients in which they are applied. Extensive disease of 
the gastrointestinal tract. generally in need of liver 
replacement because of end-stage TPN-related cirrhosis. 
The severity of illness. extent of operation performed. 
and the complexity of the postoperative care of these 
recipients are probably the most challenging in surgical 
practice today. 
The procedures described in this clinical series are 
essentially derived from the canine operations performed 
by Lillehei I and Starzl.2 These experimental models were 
first used clinically as a multi visceral procedure. and then 
as a liver intestinal variant first used by Grant et al.8 With 
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the parallel advances in organ preservation and procure-
ment. the surgical techniques necessary to provide the 
flexible application of these composite organs are ideally 
suited for the varied diseases encountered in children 
suffering from intestinal fai lure. '7 Because donor a vai labi 1-
ity has been limited. this also allows for potential sharing 
and the use of isolated intestinal grafts from donors who 
would otherwise donate the liver graft only. 
The postoperative care of these patients is extremely 
challenging and requires a multidisciplinary team with 
standardization of care specifically focused on intestinal 
transplant recipients. Fluid and electrolyte management 
as well as nutritional support can become challenging 
tasks when coupled with efforts to pursue rejection and 
sources of infection. The spectrum of potential surgical 
and clinical complications encountered in this series 
reflects not only the type of transplant operation. but also 
the severity of illness with which these patients present at 
the time of transplant. which inevitably effects survi val. 
Successful retransplamation has met with consistent 
failure in the larger composite grafts. These recipients 
inevitably suffer multisystem organ dysfunction and a 
precarious clinical state at the time of retransplamation. 
However. in the isolated intestinal transplant patient with 
a failed graft. successful retransplantation was possible 
after graft enterectomy and an II-month "rest" period. 
This type of strategy may improve even further the results 
of patient and graft survival after isolated intestinal 
transplant. Because this type of rescue operation is not an 
option for failed complex grafts. we have not performed 
the composite procedures in patients who need only the 
intestine. 
Intestinal allograft rejection remains the major stum-
bling block after intestinal transplantation. This complica-
tion may further precipitate opportunistic infections (con-
sequent to increased immunotherapy) that become additive 
factors in patient and graft losses. [n general clinical 
manifestations of intestinal disease such as abdominal 
distention. pain. diarrhea. or fever. are highly unreliable 
markers for rejection. and should be investigated by 
appropriate endoscopic procedures before any therapeu-
tic intervention is begun. By far the most effective means 
of diagnosing rejection is by serial surveillance endosco-
pies performed on a twice-a-week basis. 34 Early infiltra-
tive changes can be diagnosed before endoscopic damage 
becomes evident. or. if endoscopy findings appear signifi-
cant and diagnostic. therapeutic intervention can be 
initiated before interpretation of biopsy results. It is also 
possible to differentiate other sources of potential intesti-
nal allograft disease that may clinically mimic rejection 
such as PTLD. CMV. or other bacteriaVviral enteritis. 35 
The evidence here supports other observations that 
simultaneous liver grafting may reduce the risk of 
intestinal graft rejection.s The isolated SB graft not only 
had the highest incidence of rejection. but also required 
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more intense immunotherapy to control. as evidenced by 
the frequency ofOKT3 use. 
Infectious complications generally plaque this patient 
population, and can be of bacterial, fungal, or viral origin. 
With rejection, the intestinal graft becomes permeable to 
bacteria from within the lumen. Paradoxically, such 
bacteremias can be prevented or treated only by heavier 
immunosuppression that may contribute to worsening the 
susceptability to infection. However, maintenance of an 
intact mucosal barrier is primordial and mandates appro-
priate levels of immunosuppression. 
Our experience with CMV supports previous recom-
mendations to avoid using seropositive grafts in a sero-
negative recipient.36 The frequency of CMV disease was 
similar in the other serological groups. Although CMV 
disease produced significant morbidity. successful therapy 
of CMV was accomplished in most patients. Also. the 
patient and graft survivals in those cases of CMV disease 
was not different when compared with patients who did 
not acquire CMV disease. Thus, we support the use of 
CMV-positive donors in patients who are awaiting com-
posite grafts. because these patients generally may be too 
sick to await a seronegative donor. 
The effect on patient and graft survival with PTLD has 
been pervasive. Associated losses from uncontrollable 
rejection have been precipitated with efforts to control the 
EB V infection.!8 Results after traditional therapeutic 
interventions. which have included decrease or with-
drawal of immunosuppression. antiviral therapy, cyto-
kine therapy, and chemotherapy. have been poor. The 
development of tools such as the use of quantitative EBV 
polymerase chain reaction in the peripheral blood has 
recently allowed for early diagnosis. as well as follow-up 
of patients with established PTLD. Therapeutic interven-
tion using such a guideline has been helpful in preventing 
the end phases of this disease and may improve out-
comeY This may eventually allow us to diagnose EBV 
infection before the development of PTLD. More experi-
ence with this form of preemptive therapy. and the 
avoidance of concomitant rejection, will likely impact on 
survival. 
Clinical GVHD was significant only in one recipient 
who was a bearer of a preexisting immune deficiency and 
required reduction and then discontinuance of immuno-
suppression after an intestinal anastomotic leak. All other 
cases had minimal skin changes, which resolved sponta-
neously. The possibility of inherent immunodeficiencies 
in children will be more likely than with adults. and 
should be investigated when appropriate. It is interesting 
to note that the cases of GVHD were not found among the 
donor bone marrow-augmented patients. We have previ-
ously demonstrated the appearance of donor mononuclear 
cells in the peripheral blood of intestinal graft recipients. 
which. under the umbrella of effective immunosuppres-
sion. did not result in GVHD.39.4O This cell migration and 
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repopulation occurred concomitantly with replacement of 
lymphoreticular cells in the lamina propria of the graft by 
cells of the recipient. This had already been observed in 
recipients of liver grafts,40AI and now has subsequently 
been shown to occur in all established allografts regard-
less of the organ involved. 14,42 We have proposed that 
these events are the basis for allograft acceptance by the 
mutually cancelling effects of the coexisting leukocyte 
populations (donorlrecipient) and have initiated the ongo-
ing donor bone marrow augmentation protocol, which 
may eventually facilitate this expectation. 
Intestinal transplantation, either alone or combined 
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with other organs, has presently peaked beyond the 
developmental stage and is rapidly becoming the stan-
dard of care in the treatment of patients with complica-
tions of TPN. Survival statistics are comparable jf not 
better than those attained after lung transplantation.43 The 
rapidly evolving field has expanded the applicability of 
this procedure to diverse diseases, not only in children 
but also in adults. Patients should be referred for transplan-
tation before the development of the end-stage complica-
tions of their disease. This would allow them time to 
await appropriate organ donation, or perhaps living-
related donor procedures. 
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Discussion 
M. Langham (GaillesvilLe, FL): Dr Reyes presents a 
landmark paper, and [ congratulate you. 
First. the patient survival of 57% supports the conclu-
sion that this is rapidly becoming the standard of care. [n 
an institution that does several hundred liver transplants a 
year. an accumulated experience of 50 patients over 7 
years points out that there are not a tremendous number 
of people in the country that need this therapy. The 
detailed reports of the results, with concentration of the 
experience in one or two institutions during the learning 
curve are worthwhile. and Dr Reyes' manuscript is to be 
recommended to the audience. 
There are a couple of things [ would like to point out 
and ask about. Concerning patient survival with small 
bowel grafts only. you censored patients after graft 
enterectomy. so that the patient survival of 90% long tenn 
is misleading. In fact. several of those patients died after 
graft enterectomy and although they were not strictly 
transplant-related deaths. because there is no other therapy 
for these patients. the patients will eventually die if the 
graft fails. 
Also. I would like you to comment on use of the colon. 
Although there is no significant difference in survival 
with inclusion of the colon. you had a decrease of 20% 
I-year graft survival when you used the colon. Although 
that did not reach statistical significance. it looked like a 
real difference to me. [ wondered if you are going to 
continue to use the colon, particularly in light of your 
adult experience. 
1. Reyes (response): The success rate for small bowel 
transplanlation around the country and around the world 
has become reasonable. I included the data. specifically 
that patients who had allograft enterectomy were cen-
sored. and their survivals were tenninated at that point. I 
also included the fact that these deaths were TPN-related 
deaths and they died 91. 459. 496 days after graft 
removal. It is important to include that because these 
patients are not dying of their transplant operation. and 
this is an acceptable mode of analyzing therapeutic 
intervention that has been used for kidney and pancreas 
transplantation. Once those allografts are removed. the 
follow-up of those patients is tenninated. If we are going 
to analyze survival rates with the isolated small bowel 
graft. we need to look at survival rate with the graft and 
survival rate without the graft. because 15% of patients in 
this country right now on long-term TPN will eventually 
require intestinal transplantation. Thus. we should com-
pare survival rate with those 15% that fail. not the 85% 
that are making it on TPN. 
We have evaluated more than 200 patients. some have 
undergone transplantation in other centers. We reject 
extremely complex candidates with other comorbid sys-
tem diseases: affecting the lungs. heart. and brain. Sixty 
patients have died while on the waiting list. which reflects 
a high morbidity waiting to find an appropriate size of 
graft for these small children. Recently. we have devel-
oped a technique of reduced composite liver/small bowel 
graft. That patient is presently recovering from transplant 
and hopefully. in the future. [ will be able to present that 
type of technique. 
T.e. Moore (Palos Verdes Estates, CA): We are very 
much indebted to Starzl's Pittsburg group for tackling this 
extremely difficult problem. Your experience with 43% 
mortality and a high incidence of both immunologic and 
nonimmunologic complications suggests that this proce-
dure is barely viable. and should be perfonned only in 
Pittsburgh and a few other centers as Dr Langham has 
suggested. The long-term problems are also significant. 
Nicholas Tilney of Boston. evaluating cadaveric kidney 
transplants. found that only 20% are functioning at 10 
years. The long-tenn outcome for small bowel grafts. 
because you are starting largely with small children. is 
doubtful. With the current advances in biomedical sci-
ence and genetics we hope that in the future there will be 
much better results. I congratulate you for continuing this 
approach. Currently. one should concentrate on preven-
tion of the short gut syndrome. From the causes that you 
presented here I think 75% to 85% are preventable by 
pretenn prelabor cesarean section for gastroschisis and 
the "patch. drain. and wait" surgical approach to necrotiz-
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ing entercolitis and midgut volvulus, which would essen-
tially eliminate the short gut syndrome. 
1. Reyes: I agree with your comments. 
1. Vacanti (Boston, MA): Dr Reyes, I have a specific 
question related to the high incidence of lymphoprolifera-
tive disease. Based on your experience, do you think it's 
related specifically to the intestinal graft, or is it related to 
the overall level of immunosuppression that is required? 
1. Reyes (response): That's a very important question. 
It is related to the overall level of immunosuppression. 
Anybody who needs their FK506 levels maintained 
around 25 runs a high risk of being over immunosup-
pressed, but that's the level that we found is adequate for 
the maintenance of this graft without rejection. Other 
centers have had similar results. Until we find a protocol 
that would decrease the incidence of rejection and allow a 
lower level of FK506 administration, this is the type of 
morbidity we have to accept. With our present study of 
EBV with preemptive therapy we are able to make the 
diagnosis of EBV early, treat it more easily, and I think 
we'll decrease the morbidity of EBY. We also need a bener 
immunosuppressive protocol for this patient population. 
As far as the graft is concerned, we haven't been able 
to explain how you can get a negative EBV PTLD. We 
believe that it is related to the type of graft and to 
antigenic stimuli from the lymphocytes or histiocytes that 
we are transplanting into these patients. Presently that 
theory is involved in one of the therapeutic applications 
that we are developing. 
D. Croitoru (Norfolk, VA): What has changed over the 
last few years? The previous reports of combined liver/ 
small bowel transplantation were that you had better 
survival rates, and now you are showing that isolated 
small bowel immunosuppressant regimen or something 
else like that technique that has made a difference? 
1. Reyes (response): The first thing that has changed is 
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that we are reporting our pediatric experience separate 
from the adult experience. The adult experience signifi-
cantly changed the overall survival rate, both for the 
composite grafts and for the effect of the colon and no 
colon. With the adults the colon had a pervasive effect on 
survival from infections. 
With respect to other things, the selection of recipient 
patients and donors has improved, and the overall experi-
ence with the number of people taking care of these 
patients also has improved. CMV was previously a 
significant morbidity in our initial experience with the 
adults. We learned from them how to manipulate the 
immunosuppression, not to withdraw it significantly, and 
to treat the CMV aggressively. That accounted for a 
significant improvement in survival. 
E.S. Adkins (Wilmington, DE): In terms of strategy, 
when you have the very small patient who has obviously 
end-stage liver disease and is going to need both intestine 
and a liver, are you transplanting the liver first because 
you can't get an appropriate size intestine and liver? 
What is your approach to those little ones? 
1. Reyes (response): Currently, we are using combined 
liverlbowel. We will not do an isolated liver for two 
reasons. First, we did try twice, stimulated by Steve Dunn 
at St Christopher's Hospital who had some initially 
favorable experience but then subsequently poor, which 
he presented at the ASTS this year. We failed, and we 
stopped doing that because it is a waste of a precious 
resource. Now we do a reduced composite liver/intestine, 
trying to increase the weight ranges and increase the 
availability of organs for these patients. It is a complex, in 
situ split technique in which we are able to maintain the 
left lateral segment with the whole composite of organs, 
and give the right side to an adult recipient. It's a big 
operation and we just did our first case. The patient is 
recovering now, but we are not ready to claim success. 
